Bafna PharmaceuticalsNSE:BAFNAPH +5.00%60 Days Inventory is 88.69 as of Mar. 2026, which is 16% below its 10-year median of 104.99. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹91.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 916 Drug Manufacturers companies, Bafna Pharmaceuticals ranks better than 77.4% on this metric.
The historical rank and industry rank for Bafna Pharmaceuticals's Days Inventory or its related term are showing as below:
NSE:BAFNAPH'
s Days Inventory Range Over the Past 10 Years
Min: 88.53 Med: 104.99 Max: 139.75
Current: 104.46
During the past 13 years, Bafna Pharmaceuticals's highest Days Inventory was 139.75. The lowest was 88.53. And the median was 104.99.
NSE:BAFNAPH's Days Inventory is ranked better than 77.4% of 916
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs NSE:BAFNAPH: 104.46
Bafna Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (96.41) to Mar. 2026 (88.69).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Bafna Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 1.03.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bafna Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.68.
Bafna Pharmaceuticals (NSE:BAFNAPH) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Bafna Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bafna Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Bafna Pharmaceuticals Days Inventory Related Terms
Bafna Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BAFNAPH vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Days Inventory of 88.69 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Bafna Pharmaceuticals and its competitors. This is 16% below median its historical median of 104.99. Over the past decade, Bafna Pharmaceuticals' Days Inventory has ranged from 88.53 to 139.75. According to the industry distribution chart, Bafna Pharmaceuticals ranks #207 out of 916 companies in the Drug Manufacturers industry, placing it in the top 22.6%.
Is Bafna Pharmaceuticals' Days Inventory too high?
Bafna Pharmaceuticals' current Days Inventory of 88.69 is 16% below median its 10-year median of 104.99. Over the past 10 years, this metric has ranged from a low of 88.53 to a high of 139.75. The Drug Manufacturers industry median Days Inventory is 164.43. Bafna Pharmaceuticals' value of 88.69 is 46.1% below this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #207 out of 916 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #207 out of 916 companies for Days Inventory. This places Bafna Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.43. Bafna Pharmaceuticals' value of 88.69 is 46.1% below this benchmark. Historically, Bafna Pharmaceuticals' own Days Inventory has ranged from 88.53 to 139.75 over the past decade. While the company's 10-year median is 104.99 vs. the industry median of 164.43, Bafna Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current Days Inventory of 88.69 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Days Inventory is 88.69, which is 16% below median its own 10-year median of 104.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.79, compared to a current price of ₹214.63 — trading 133.8% above its estimated fair value. The current Days Inventory is 88.69, which is 16% below median its 10-year median of 104.99 and 46.1% below the Drug Manufacturers industry median of 164.43. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Days Inventory is 88.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹214.63 is trading 133.8% above its estimated GF Value™ of ₹91.79.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Days Inventory: 88.69 (16% below median its 10-year median of 104.99)
GF Value™: ₹91.79 vs. price of ₹214.63 (133.8% above fair value)
Industry Position: 46.1% below the Drug Manufacturers median (#207 of 916)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
